261780.KQ CHA Vaccine Institute Co. Ltd.
- Market cap
- KRW 90.2B
- P/E
- -
- P/B
- 9.12x
- ROE
- -95.8%
- Dividend yield
- -
- Fundamental score
- 0.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 261780.KQ undervalued?
Graham numberThe Graham number of CHA Vaccine Institute Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CHA Vaccine Institute Co. Ltd. fundamental analysis
2 of 21 checks passedROE 0/2
Low return on equity (-95.8%), below 10%.
ROA 0/1
Return on assets (-44.8%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-58.0%) is below the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 4.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (9.1x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
CHA Vaccine Institute Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CHA Vaccine Institute Co. Ltd.
AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally,…
Full company profileCHA Vaccine Institute Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CHA Vaccine Institute Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 126M | 77.8M | 500M | 179M | 294M | 371M | 159M | - |
| Gross Profit | 86.1M | 64.8M | 500M | 160M | 260M | 347M | 144M | - |
| Operating Income | -2.87B | -4.23B | -6.08B | -6.47B | -6.42B | -7.73B | -14.3B | -8.33B |
| EBITDA | - | - | - | -3.73B | 1.06B | -8.64B | -13.4B | -7.83B |
| Net Income | -2.98B | -6.24B | -18.4B | -6.72B | -1.75B | -10.1B | -16.0B | -9.47B |
| EPS | -113 | -236 | -697 | -254 | -65 | -378 | -597 | -353 |
| Balance Sheet | ||||||||
| Total Assets | 9.56B | 25.7B | 65.3B | 61.1B | 45.1B | 47.2B | 29.8B | 21.1B |
| Total Liabilities | 18.4B | 24.2B | 25.7B | 27.7B | 9.70B | 19.5B | 17.9B | 11.3B |
| Shareholders' Equity | -8.83B | 1.57B | 39.6B | 33.4B | 35.4B | 27.7B | 11.9B | 9.89B |
| Cash & Short-term Investments | 8.88B | 24.8B | 61.5B | 57.8B | 38.9B | 40.1B | 9.77B | 6.94B |
| Total Debt | 5.22B | 18.7B | - | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.09B | -3.95B | -4.74B | -5.19B | -5.29B | -8.10B | -11.0B | -8.78B |
| Capital Expenditure | 124M | 53.5M | 683M | 447M | 291M | 235M | 156M | 33.8M |
| Free Cash Flow | - | -4.01B | -5.42B | -5.64B | -5.58B | -8.33B | -11.2B | -8.81B |
| Ratios | ||||||||
| ROE | - | -396.7% | -46.5% | -20.1% | -4.9% | -36.6% | -135.3% | -95.8% |
| ROA | -31.2% | -24.2% | -28.2% | -11.0% | -3.9% | -21.5% | -53.9% | -44.8% |
| Net Profit Margin | -2,363.1% | -8,021.4% | -3,684.0% | -3,741.4% | -594.8% | -2,735.2% | -10,115.3% | - |
| Debt to Equity | - | 11.91x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CHA Vaccine Institute Co. Ltd. dividends
CHA Vaccine Institute Co. Ltd. has not paid dividends in the last 7 fiscal years.
Who owns CHA Vaccine Institute Co. Ltd.
- Insiders 18.40%
- Institutions 0.00%
- Public & others 81.61%
- Shares outstanding 26.9M
- Free float 19.3M
CHA Vaccine Institute Co. Ltd. company profile
- Company name
- CHA Vaccine Institute Co. Ltd.
- Ticker
- 261780.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Fiscal year end
- December
- Address
- Byucksan Technopia, Seongnam-si, South Korea, 13230
- Phone
- 82 3 1881 7327
About CHA Vaccine Institute Co. Ltd.
AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally, an influenza vaccine for seasonal flu, recombinant MBL for infectious disease suppression, and a TB booster vaccine. The company also develops 3rd-generation Hepatitis B vaccine (CVI HBV 001), a preventive vaccine using 3rd generation recombinant antigens; Hepatitis B therapeutic vaccine (CVI HBV 002), a therapeutic vaccine for treatment of patients and carriers of chronic hepatitis B; Shingles vaccine (CVI VZV 001), for prevention of shingles and postherpetic neuralgia; Next generation flu vaccine, quadrivalent influenza vaccine; Immunostimulant, TLR ligand based immunoreactive substances for immune response to vaccines; Recombinant MBL, immunotherapeutic substances infections by viruses and bacteria. The company was formerly known as CHA Vaccine Research Institute and changed its name to AriBioLab Co.,Ltd. in May 2026. AriBioLab Co.,Ltd. was incorporated in 2000 and is headquartered in Seongnam-si, South Korea.
CHA Vaccine Institute Co. Ltd. management
3- JaeJun JeongCEO & Director · born 1959
- Hong Mo MoonFounder
- Kim SuhyungCFO & Director · born 1986